中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [6]
金属研究所 [1]
上海微系统与信息技术... [1]
上海生物化学与细胞生... [1]
上海营养与健康研究所 [1]
生态环境研究中心 [1]
更多
采集方式
OAI收割 [11]
内容类型
期刊论文 [11]
发表日期
2021 [1]
2020 [1]
2019 [2]
2018 [2]
2017 [1]
2014 [2]
更多
学科主题
Gastroente... [1]
Oncology [1]
Pharmacolo... [1]
Science & ... [1]
筛选
浏览/检索结果:
共11条,第1-10条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
作者升序
作者降序
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
期刊论文
OAI收割
ADVANCED MATERIALS, 2021, 页码: 37
作者:
Saeed, Madiha
;
Chen, Fangming
;
Ye, Jiayi
;
Shi, Yang
;
Lammers, Twan
  |  
收藏
  |  
浏览/下载:57/0
  |  
提交时间:2021/08/17
clinical translation
nanobiomaterials
nanovaccines
normalization cancer immunotherapy
primary and adaptive resistance
tumor immune microenvironment
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant
期刊论文
OAI收割
CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287
作者:
Hu, Xianglong
;
Xun, Qiuju
;
Zhang, Tao
;
Zhu, Su-Jie
;
Li, Qian
  |  
收藏
  |  
浏览/下载:100/0
  |  
提交时间:2020/07/01
EGFR(C797S) mutant
SARs
2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine
Clinical resistance
Fourth-generation inhibitors
The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex
期刊论文
OAI收割
INTERNATIONAL JOURNAL OF CANCER, 2019, 卷号: 145, 期号: 10, 页码: 2840-2849
作者:
Wang, Shixiang
;
Zhang, Jing
;
He, Zaoke
;
Liu, Xue-Song
;
Wu, Kai
  |  
收藏
  |  
浏览/下载:24/0
  |  
提交时间:2020/12/21
PD-1 BLOCKADE
CLINICAL-RESPONSE
SOLID TUMORS
NIVOLUMAB
IPILIMUMAB
PEMBROLIZUMAB
CHEMOTHERAPY
RESISTANCE
LANDSCAPE
DOCETAXEL
Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis
期刊论文
OAI收割
NATURE, 2019, 卷号: 571, 期号: 7764, 页码: 275-+
作者:
Zhou, Changyang
;
Zuo, Erwei
;
Han, Linxiao
;
Wei, Yu
;
Hu, Xinde
  |  
收藏
  |  
浏览/下载:39/0
  |  
提交时间:2020/12/09
aging
amphiregulin
cancer resistance
clinical biomarker
combinational treatment
programmed cell death 1 ligand
senescence-associated secretory phenotype
stroma
Discovery of JND3229 as a New EGFR(C797S) Mutant Inhibitor with In Vivo Monodrug Efficacy
期刊论文
OAI收割
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 卷号: 9, 期号: 11, 页码: 1123-1127
作者:
Lu, Xiaoyun
;
Zhang, Tao
;
Zhu, Su-Jie
;
Xun, Qiuju
;
Tong, Lingjiang
  |  
收藏
  |  
浏览/下载:125/0
  |  
提交时间:2019/01/08
EGFR(C797s)
Clinical resistance
Fourth-generation nhibitors
Monodrug efficacy
Review of antibiotic resistance in China and its environment
期刊论文
OAI收割
ENVIRONMENT INTERNATIONAL, 2018, 卷号: 110, 页码: 160-172
作者:
Qiao, Min
;
Ying, Guang-Guo
;
Singer, Andrew C.
;
Zhu, Yong-Guan
  |  
收藏
  |  
浏览/下载:32/0
  |  
提交时间:2019/06/17
Antibiotics
Antibiotic resistance gene
Environment
Clinical setting
Planetary health
Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment
期刊论文
OAI收割
FRONTIERS OF MEDICINE, 2017, 卷号: 11, 期号: 3, 页码: 340-348
作者:
Xu Tianhua
;
Sheng Zitong
;
Yao Li
  |  
收藏
  |  
浏览/下载:27/0
  |  
提交时间:2021/02/02
RENAL INJURY
WEIGHT-LOSS
LIPID-ACCUMULATION
INSULIN-RESISTANCE
BARIATRIC SURGERY
KIDNEY
REDUCTION
LEPTIN
DIET
HYPERFILTRATION
obesity-related glomerulopathy
pathogenesis
pathologic
clinical characteristics
Molecularly targeted cancer therapy: some lessons from the past decade
期刊论文
OAI收割
TRENDS IN PHARMACOLOGICAL SCIENCES, 2014, 卷号: 35, 期号: 1, 页码: 41-50
作者:
Huang, Min
;
Shen, Aijun
;
Ding, Jian
;
Geng, Meiyu
  |  
收藏
  |  
浏览/下载:33/0
  |  
提交时间:2019/01/08
tumor heterogeneity
resistance
personalized medicine
biomarker
co-clinical trial
BCRP-targeted reverse of multidrug resistance: research progress and drug development
期刊论文
OAI收割
Chinese Pharmacological Bulletin, 2014, 卷号: 30, 期号: 5, 页码: 615-618
作者:
Yu Cunzhi
;
Qi Xinming
;
Ren Jin
  |  
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2019/01/08
BCRP
breast cancer resistance protein (BCRP)
tumor multidrug resistance
expression regulation
subcellular localization
energy dependence
transport activity inhibition
clinical drug strategy
drug development